Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality

Blood

Volumn 124, Issue 2, 2014, Pages 287-295

  Sorror, Mohamed L ^a,b   Martin, Paul J ^a,b   Storb, Rainer F ^a,b   Bhatia, Smita ^c   Maziarz, Richard T ^d,e   Pulsipher, Michael A ^f,g   Maris, Michael B ^h   Davis, Christopher ^a   Deeg, H Joachim ^a,b   Lee, Stephanie J ^a,b   Maloney, David G ^a,b   Sandmaier, Brenda M ^a,b   Appelbaum, Frederick R ^a,b   Gooley, Theodore A ^a,i  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; NONMYELOABLATIVE CONDITIONING; ORGAN DONOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COMORBIDITY; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84904133696     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-550566     Document Type: Article

References (74)

1. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79-91. (Pubitemid 20357658)
2. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583. (Pubitemid 351377826)
3. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80(7):1838-1845.
4. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51(6):1197-1203.
5. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119(17):3908-3916.
6. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530-1538.
7. Andersen J, Heilmann C, Jacobsen N, Nielsen C, Bendtzen K, Müller K. Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37(7):635-640.
8. Jagasia M, Arora M, Flowers MED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296-307.
9. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. [Review] Lancet. 2009;373(9674):1550-1561.
10. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. [Review] Mol Ther. 2006;13(1):26-41. (Pubitemid 41763480)
11. Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26(35):5728-5734.
12. Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
13. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148(6):1687-1698. (Pubitemid 9084041)
14. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. [Review] Blood. 2001;98(12):3192-3204.
15. Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol. 1999;52(1):27-37. (Pubitemid 29064271)
16. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-4613. (Pubitemid 351377830)
17. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455-468.
18. Hurria A, Browner IS, Cohen HJ, et al. Senior adult oncology. J Natl Compr Canc Netw. 2012;10(2):162-209.
19. Raimondi R, Tosetto A, Oneto R, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood. 2012;120(6):1327-1333.
20. Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT outcomes at US transplant centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) study. [abstract] Blood. 2012;120(733).
21. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854-2863.
22. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
23. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14(3):282-289. (Pubitemid 351218198)
24. Pavlů J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115(20):4018-4020.
25. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341-350.
26. Maruyama D, Fukuda T, Kato R, et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant. 2007;13(8):932-941. (Pubitemid 47055387)
27. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254. (Pubitemid 47554249)
28. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515-3520. (Pubitemid 28525174)
29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
30. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
31. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3(2):143-152. (Pubitemid 14052973)
32. Harrell FE Jr, Margolis PA, Gove S, et al WHO/ARI Young Infant Multicentre Study Group. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. [Review] Stat Med. 1998;17(8):909-944. (Pubitemid 28185168)
33. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. [Review] Stat Med. 1996;15(4):361-387. (Pubitemid 26072233)
34. Imamura M. Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation. Int J Hematol. 2002;76(Suppl 1):191-194.
35. Gaziev D, Polchi P, Galimberti M, et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation. 1997;63(6):854-860. (Pubitemid 27150593)
36. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. [Review] Cell. 2006;124(4):783-801. (Pubitemid 43261452)
37. Finke J, Schmoor C, Bethge WA, et al ATG-Fresenius Trial Group. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant. 2012;18(11):1716-1726.
38. Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555-1562.
39. Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937-947.
40. Wagner JE, Thompson JS, Carter SL, Kernan NA; Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366(9487):733-741. (Pubitemid 41207235)
41. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012;119(22):5311- 5319.
42. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. [Review] Blood. 2013;121(4):585-594.
43. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163.
44. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755. (Pubitemid 44061380)
45. Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? [Review] Curr Stem Cell Res Ther. 2012;7(3):229-239.
46. Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol. 2006;15(3):223-227. (Pubitemid 43129390)
47. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood. 1990;75(4):1011-1016. (Pubitemid 20067204)
48. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17(6):1150-1156. (Pubitemid 36722247)
49. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant. 2001;28(2):197-200. (Pubitemid 32725721)
50. Oxholm P. Primary Sjögren's syndrome: clinical and laboratory markers of disease activity. [Review] Semin Arthritis Rheum. 1992;22(2):114-126.
51. Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics: an update. [Review] Eur J Pharmacol. 2008;579(1-3):1-12.
52. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012;32(3):639-643.
53. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. [Review] J Gastroenterol Hepatol. 2011;26(Suppl 1):188-202.
54. Sakamoto A, Ishizaka N, Saito K, et al. Serum levels of IgG4 and soluble interleukin-2 receptor in patients with coronary artery disease. Clin Chim Acta. 2012;413(5-6):577-581.
55. Madonna R, Cevik C, Nasser M, De Caterina R. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. [Review] Thromb Haemost. 2012;107(4):656-661.
56. Seidler S, Zimmermann HW, Weiskirchen R, Trautwein C, Tacke F. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. BMC Gastroenterol. 2012;12:38.
57. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. [Review] J Cereb Blood Flow Metab. 2012;32(9):1677-1698.
58. Kawayama T, Okamoto M, Imaoka H, Kato S, Young HA, Hoshino T. Interleukin-18 in pulmonary inflammatory diseases. [Review] J Interferon Cytokine Res. 2012;32(10):443-449.
59. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor in infectious disease. [Review] J Pathol. 2013;230(2):132-147.
60. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A, Di Biase M. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest. 2012;42(4):371-375.
61. Nakamura H, Komatsu K, Ayaki M, et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versushost disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol. 2000;106(1 Pt 2):S45-S50. (Pubitemid 30482834)
62. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102(2):756-762. (Pubitemid 36842003)
63. Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. [Review] Curr Opin Oncol. 2009;21(Suppl 1):S39-S41.
64. Storb R, Gyurkocza B, Storer BE, et al. Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. Biol Blood Marrow Transplant. 2013;19(5):792-798.
65. Gironella M, Iovanna JL, Sans M, et al. Antiinflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005;54(9):1244-1253. (Pubitemid 41192482)
66. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versushost disease. Blood. 2011;118(25):6702-6708.
67. Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119(12):2960-2963.
68. Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118(6):1685-1692.
69. Ward NL, Dumont DJ. The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. [Review] Semin Cell Dev Biol. 2002;13(1):19-27. (Pubitemid 35418311)
70. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. [Review] Autoimmun Rev. 2011;10(10):590-594.
71. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? [Review] Biomarkers. 2011;16(Suppl 1):S11-S21.
72. Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. [Review] Cold Spring Harb Perspect Med. 2012;2(9):a006550.
73. Lorbeer R, Baumeister SE, Dörr M, et al. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail. 2013;15(12):1327-1334. [Epub ahead of print 2013 Jul 30].
74. López-Mejías R, Corrales A, Genre F, et al. Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2013;31(5):761-766.